<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01818024</url>
  </required_header>
  <id_info>
    <org_study_id>116343</org_study_id>
    <nct_id>NCT01818024</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers</brief_title>
  <official_title>A Three Part, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of Inhaled and Intravenous GSK2862277 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a 3 part study to investigate the safety, tolerability, pharmacokinetics and
      pharmacodynamics of single and repeat doses of GSK2862277 administered via inhalation (IH) or
      intravenous (IV) routes in healthy subjects.

      Part 1 of this study will involve an initial assessment of safety, tolerability and
      pharmacokinetics of GSK286227, via single escalating intravenous doses, compared to a
      predecessor molecule, GSK1995057. After completion of Part 1 an interim data review will
      occur which will assess key comparability criteria to inform progression to Part 2 of the
      study.

      Part 2 of the study will involve single doses of GSK2862277 at a level predicted to be at or
      close to therapeutic dose levels. Part 2 will investigate both intravenous and inhaled routes
      of administration, in sequential manner, respectively. An interim data review will also occur
      after completion of Part 2, where all data accumulated previously will be assessed to examine
      appropriateness to progress to Part 3.

      Part 3 of the study will involve 5 days of repeat dosing via both inhaled and intravenous
      routes using the same dose administered in Part 2.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2013</start_date>
  <completion_date type="Actual">October 25, 2013</completion_date>
  <primary_completion_date type="Actual">October 25, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single IV or IH dose of GSK2862277 assessed by number of subjects with adverse events (AE)s in Part 1 and Part 2</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Safety and tolerability parameters will include recording of adverse events (AEs), throughout the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of repeat IV or IH dose of GSK2862277 assessed by number of subjects with AEs in Part 3</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Safety and tolerability parameters will include recording of AEs, throughout the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single IV or IH dose of GSK2862277 assessed by laboratory tests in Part 1 and Part 2</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Laboratory tests will include haemogram, clinical chemistry, urine examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of repeat IV or IH dose of GSK2862277 as assessed by laboratory tests in Part 3</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Laboratory tests will include haemogram, clinical chemistry, urine examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single IV or IH dose of GSK2862277 assessed by vital signs in Part 1 and Part 2</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Vital signs will include blood pressure (BP), heart rate respiration rate and body temperature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of repeat IV or IH dose of GSK2862277 assessed by vital signs in Part 3</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Vital signs will include BP, heart rate respiration rate and body temperature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single IV or IH dose of GSK2862277 assessed by ECG in Part 1 and Part 2</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Safety data will include electrocardiogram (ECG) readings obtained at each timepoint during the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of repeat IV or IH dose of GSK2862277 assessed by ECG in Part 3</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Safety data will include ECG readings obtained at each timepoint during the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single IV or IH dose of GSK2862277 assessed by spirometry monitoring in Part 1 and Part 2</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Spirometry monitoring will include forced expiratory volume in one second (FEV1) and forced vital capacity (FVC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of repeat IV or IH dose of GSK2862277 assessed by spirometry monitoring in Part 3</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Spirometry monitoring will include FEV1 and FVC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single IV dose of GSK2862277 as assessed by measurement of plasma cytokines in Part 1</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Blood samples will be collected for assessment of plasma cytokines.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity in subjects receiving single IV or IH dose of GSK2862277 in Part 1 and Part 2</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Presence of anti GSK2862277 binding antibodies will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity in subjects receiving repeat IV or IH dose of GSK2862277 in Part 3</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Presence of anti GSK2862277 binding antibodies will be evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters in subjects receiving single IV or IH dose of GSK2862277 in Part 1 and Part 2</measure>
    <time_frame>Up to 48 hours post dose</time_frame>
    <description>The blood samples will be collected for plasma concentrations of GSK2862277.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters in subjects receiving repeat IV dose of GSK2862277 in Part 3 Cohort 3a</measure>
    <time_frame>Up to 48 hours post last dose</time_frame>
    <description>The blood samples will be collected for plasma concentrations of GSK2862277.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters in subjects receiving repeat IH dose of GSK2862277 in Part 3 Cohort 3b</measure>
    <time_frame>Up to 48 hours post last dose</time_frame>
    <description>The blood samples will be collected for plasma concentrations of GSK2862277</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters in subjects receiving single IV dose of GSK2862277 in Part 1</measure>
    <time_frame>Up to 48 hours post last dose</time_frame>
    <description>The PK parameters will be compared with historic GSK1995057 PK data in Part 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic and immune function biomarkers in serum of subjects receiving single IV or IH dose of GSK2862277 in Part 1 and Part 2</measure>
    <time_frame>Up to 48 hours post last dose</time_frame>
    <description>The pharmacodynamic and immune function biomarkers in serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic and immune function biomarkers in serum of subjects receiving repeat IV or IH dose of GSK2862277in Part 3</measure>
    <time_frame>Up to 48 hours post last dose</time_frame>
    <description>The pharmacodynamic and immune function biomarkers in serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in IL-8 expression in ex vivo WBA in subjects receiving single IV 0.05 mg/kg dose of GSK2862277 in Part 1 in Cohort1c</measure>
    <time_frame>Up to 12 hours post dose</time_frame>
    <description>IL-8 expression in ex vivo whole blood essay (WBA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of urine parameters in subjects receiving single IV 2 mg/kg dose of GSK2862277 in Part 2 in Cohort 2a</measure>
    <time_frame>Up to 48 hours post dose</time_frame>
    <description>The urine samples will be collected for urine concentrations of GSK2862277.</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Respiratory Disorders</condition>
  <arm_group>
    <arm_group_label>Part 1: Cohort 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV dose of GSK2862277 as a continuous infusion over 2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV dose of GSK2862277 as a continuous infusion over 3 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort 1c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV dose of GSK2862277 as a continuous infusion over 3 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort 2a GSK2862277</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV dose of GSK2862277 as a continuous infusion over 1 hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort 2a Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matching placebo will be administered as a continuous IV infusion over 1 hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort 2b GSK2862277</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IH dose of GSK2862277.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort 2b Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matching placebo will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Cohort 3a GSK2862277</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV dose of GSK2862277 (decided from Part 2) as a continuous infusion over 1 hour for daily 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Cohort 3a Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matching placebo will be administered as IV infusion over 1 hour daily for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Cohort 3b GSK2862277</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeat IH dose of GSK2862277 (decided from Part 2) daily for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Cohort 3b Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matching placebo will be administered as IH daily for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single IV dose of GSK2862277</intervention_name>
    <description>GSK2862277 solution available in a 40 mg vial for IV administration.</description>
    <arm_group_label>Part 1: Cohort 1c</arm_group_label>
    <arm_group_label>Part 1: Cohort 1b</arm_group_label>
    <arm_group_label>Part 2: Cohort 2a GSK2862277</arm_group_label>
    <arm_group_label>Part 1: Cohort 1a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo single dose IV infusion</intervention_name>
    <description>Matching placebo solution available for IV administration.</description>
    <arm_group_label>Part 2: Cohort 2a Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single IH dose of GSK2862277</intervention_name>
    <description>GSK2862277 nebulised solution available in a 40 mg vial for IH administration.</description>
    <arm_group_label>Part 2: Cohort 2b GSK2862277</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo single dose IH</intervention_name>
    <description>Matching placebo nebulised solution available for IH administration.</description>
    <arm_group_label>Part 2: Cohort 2b Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repeat IV dose of GSK2862277</intervention_name>
    <description>GSK2862277 solution available in a 40 mg vial for IV administration.</description>
    <arm_group_label>Part 3: Cohort 3a GSK2862277</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo repeat dose IV infusion</intervention_name>
    <description>Matching placebo solution available for IV administration.</description>
    <arm_group_label>Part 3: Cohort 3a Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repeat IH dose selected of GSK2862277 from Part 2</intervention_name>
    <description>GSK2862277 nebulised solution available in a 40 mg vial for IH administration.</description>
    <arm_group_label>Part 3: Cohort 3b GSK2862277</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo repeat dose IH</intervention_name>
    <description>Matching placebo nebulised solution available for IH administration.</description>
    <arm_group_label>Part 3: Cohort 3b Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between 18 and 65 years of age inclusive, at the time of signing the
             informed consent.

          -  Healthy as determined by a responsible and experienced physician, based on a medical
             evaluation including medical history, physical examination, laboratory tests and
             cardiac monitoring. A subject with a clinical abnormality or laboratory parameters
             outside the reference range for the population being studied may be included only if
             the Investigator and the GSK Medical Monitor agree that the finding is unlikely to
             introduce additional risk factors and will not interfere with the study procedures.

          -  Subject is positive at screening for HAVH autoantibodies against GSK1995057 (Part 1
             only).

          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
             result within 3 months of screening

          -  A positive pre-study drug/alcohol screen.

          -  A positive test for human immunodeficiency virus (HIV) antibody.

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day.

        Exclusion Criteria:

          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
             result within 3 months of screening

          -  A positive pre-study drug/alcohol screen.

          -  A positive test for human immunodeficiency virus (HIV) antibody.

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA13UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/116343?search=study&amp;search_terms=116343#rs</url>
    <description>Results for study 116343 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2013</study_first_submitted>
  <study_first_submitted_qc>March 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2013</study_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy volunteer</keyword>
  <keyword>TNFR1</keyword>
  <keyword>domain antibody</keyword>
  <keyword>Lung injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>116343</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116343</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116343</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116343</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116343</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116343</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116343</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

